API SUPPLIERS

API Suppliers

38

US DMFs Filed

23

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

37

API Market Place

28

INTERMEDIATES

3

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS

293

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

3

News

33

REF STANDARD

EDQM

3

USP

5

JP

0

Other Listed Suppliers

8

SERVICES

3

Full Screen View

Sen-Jam Pharmaceutical

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease

Details:

Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.

Lead Product(s): Naproxen,Fexofenadine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: SJP-001

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2022

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for AM20060551

AM20060551

AM20060551

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

38 API Suppliers

23 USDMF

11 CEP/COS

1 JDMF

3 EU WC

37 KDMF

14 NDC API

15 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

3 Suppliers

DOSSIERs // Finished Dosage Formulations

308 Dossiers

113 FDA Orange Book

82 Europe

29 Canada

23 Australia

25 South Africa

36 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 250MG

TABLET;ORAL - 375MG

TABLET;ORAL - 500MG

SUSPENSION;ORAL - 25MG/ML

TABLET, DELAYED RELEASE;ORAL - 375MG

TABLET, DELAYED RELEASE;ORAL - 500MG

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

33 BASF

32 Kerry

27 Roquette

14 Corel Pharma Chem

14 Seppic

13 Ideal Cures Pvt Ltd

12 Microlex e.U

12 Sigachi Industries

12 Gangwal Chemicals

10 Gangwal Healthcare

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

10 Boai NKY Pharmaceuticals Ltd

8 Actylis

6 DFE Pharma

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

6 Nanjing Well Pharmaceutical

6 SPI Pharma

6 Lonza Capsugel

4 Ingredion Pharma Solutions

4 Ulanqab Kema New Material

4 Vasa Pharmachem

4 Pharmatrans-Sanaq

4 Prachin Chemical

3 Kima Chemical

3 Doshion Polyscience

3 DKSH

2 Alcedo Pharmachem

2 Seqens

2 Finar

2 Nomisma Healthcare

2 Jai Radhe Sales

2 The Dow Chemical Company

2 Aeon Procare

2 Evonik

1 Pfanstiehl

1 Vertellus

1 Nanjing Bold Chemical

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons